Abstract 2797
Background
Neoadjuvant chemotherapy is an accepted treatment method to improve the survival for advanced gastric cancer in worldwide. This phase II study, KSCC1601, aimed to investigate efficacy and safety of S-1 and Oxaliplatin for locally advanced gastric (LAGC) and esophago-gastric cancer (EGC).
Methods
Patients received oral S-1 40-60 mg twice daily on days 1 to 14 every 3 weeks plus intravenous oxaliplatin 130 mg/m2 on day 1 every 3 weeks for 3 courses, followed by gastrectomy with D2 lymphadenectomy. The primary endpoint was pathological response rate (pRR) according to the proportion of necrosis in the tumor: grade 0, no necrosis; grade 1a, < 1/3 necrosis; grade 1b, > 1/3 or < 2/3 necrosis; grade 2, > 2/3 or < all necrosis; and grade 3, all parts of the tumors affected by necrosis. A sample size of 46 was set according to one-sided significance level of 0.05 and power of 80% based on an exact binomial distribution, and assuming the null hypothesis of a 30% pRR and an alternative hypothesis of a 50% pRR. The incidence of anastomosis leakage in EGC was the main secondary endpoint. Other secondary endpoints were R0 resection rate, overall survival, relapse free survival and safety.
Results
Between 2016 April and 2017 July, 47 patients (24 EGC, 23 LAGC) were enrolled in this study. All patients were eligible for analysis. 42 patients (89.4%:95%CI 76.9-96.5) underwent surgery, and curative resection was performed in 41 patients. The rate of protocol treatment completeness was 42 patients (89.4%:95%CI 76.9-96.5%). pRR, the primary endpoint (grade 1b to 3), was 25 cases (59.5%:90%CI 45.7-72.3%) of primary lesions. The main toxicities of neoadjuvant chemotherapy were grade 3/4 thrombocytopenia (10.6%), neutropenia (6.4%), anemia (4.3%), grade 3/4 anorexia (12.8%). The number of anastomosis leakage so as to 20 EGC according to the Clavien–Dindo classification was 2 for grade IIIa, 2 for grade IIIb, and 1 for grade IV (25.0%:90%CI 10.4-45.6%). Survival data will be updated in further investigation.
Conclusions
The S-1 and oxaliplatin was well tolerated and is promising as a preoperative chemotherapy regimen for patients with LAGC and EGC.
Clinical trial identification
UMIN000021061.
Legal entity responsible for the study
KSCC.
Funding
Yakult Honsha Co., Ltd., Cres Kyushu.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract